1 / 81

Breast MRI at Lowell General Hospital

Breast MRI at Lowell General Hospital. Jonas Berman, MD January 21, 2009. Lowell General Hospital. “In this defining moment, a change has come to Lowell General”. Breast Cancer Overview. >250,000 new cases diagnosed each year 2 nd leading cause of cancer deaths in women.

lieu
Download Presentation

Breast MRI at Lowell General Hospital

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Breast MRIat Lowell General Hospital Jonas Berman, MD January 21, 2009

  2. Lowell General Hospital

  3. “In this defining moment,a change has come to Lowell General”

  4. Breast Cancer Overview • >250,000 new cases diagnosed each year • 2nd leading cause of cancer deaths in women

  5. Of newly diagnosed cases of breast cancer, more than half are candidates for breast conservation

  6. Various studies indicate that 15%-50% of patients with known breast cancer will have their management altered by further evaluation with ultrasound or breast MRI

  7. Of these patients whose management is altered, 30%-50% will be demonstrated to have other foci of malignancy.

  8. When an MRI of the breast identifies a lesion not originally identified on conventional imaging, a second, focused ultrasound will identify 50% of these lesions, which can then be biopsied conventionally. The other 50% need MRI guided biopsy.

  9. Background: What is MRI? • 􀂉 Uses magnetic fields to produce detailed cross-sectional images of tissue structures • 􀂉 Uses injected contrast agents to distinguish fat, glandular tissue, lesions, etc. in the breast • 􀂉 Different factors contribute to the measured signal that determines the brightness of the tissues in the image • 􀂉 Contrast agent provides reliable detection of cancers and other lesions. • 􀂉 Screening MRI requires appropriate techniques and equipment (including dedicated breast MRI equipment) and experienced staff

  10. Technical Requirements For Good Cancer Detection: • High-field breast MRI (1.5T or >) • Gadolinium-DTPA injection • Dedicated bilateral breast coil • Good fat suppression techniques • High-resolution 3D gradient echo pulse sequence

  11. Contraindications Cardiac pacemakers, Ferromagnetic intracranial aneurysm clips Neurostimulators Cochlear implants Ferromagnetic implants, devices, foreign bodies, electronic devices. ACR practice guideline

  12. Pregnancy/Lactation No known adverse effects Gadolinium does cross placenta into fetus minimally secreted in breast milk ACR practice guideline

  13. Clinical Indications for Contrast enhancedBreast MRI: • Search for primary breast cancer in women with a positive axillary node • Staging of tumor extent in women with a known breast cancer – MRI most accurate • Search for multifocal, multicentric or bilateral breast cancer in women with a known breast cancer

  14. Clinical Indications for Contrast enhancedBreast MRI: • Search for residual tumor shortly after surgery in patients with + margins • Evaluation for tumor recurrence after surgery and/or radiation • Monitoring tumor size and extent in neoadjuvant chemotherapy • Screening of high-risk women

  15. Why Gadolinium is Essentialfor Cancer Detections T1W-Gradient-echo Pre- Gd T1W-Gradient-echo 2 minute Post Gd

  16. Why Gadolinium is Essentialfor Cancer Detection T1W-Gradient-echo 2 minute Post Gd T1W-Gradient-echo Pre-Gd

  17. Subtraction Image Sagital Maximum Intensity Projection (MIP)

  18. Gadolinium Kinetics Enhancement Kinetics • Rate-how fast • Percent-how much in • Washout- how fast out

  19. “Screening” MRI • Who is at High Risk? • 􀂉 Family history suggestive of inherited gene mutation; risk is calculated by assessment models/tools • 􀂉 Genetic testing for mutation in BRCA1/2, TP53, or PTEN • 􀂉 Review of clinical history • 􀂾 Treated for Hodgkin disease • 􀂾 LCIS, ALH • 􀂾 ADH, DCIS • 􀂾 High mammographic density • 􀂾 Personal history of breast cancer

  20. Summary of ACS Recommendations (2007) • Recommend Annual MRI Screening (based on evidence) • BRCA mutation • 1st degree relative of BRCA carrier, but untested • Lifetime risk ~20-25% or greater, as defined by BRCAPRO or other models that are largely dependent on family history

  21. Summary of ACS Recommendations cont’d • Recommend Annual MRI Screening (based on expert consensus opinion) • Radiation to chest (e.g. Hodgkin disease survivors) between ages 10-30 • Li Fraumeni syndrome,Cowden, Bannayan-Riley-Ruvalcaba syndromes

  22. Summary of ACS Recommendations cont’d • Insufficient Evidence to Recommend For or Against MRI Screening • Lifetime risk 15-20%, as defined by BRCAPRO or other models that are largely dependent on family history • LCIS, ALH, ADH • Dense breast tissue • Personal history of breast cancer, including DCIS

  23. Summary of ACS Recommendations cont’d • Recommend Against MRI Screening (based on expert consensus opinion) • Women at <15% lifetime risk

  24. Breast Cancer Risks for Hypothetical Patients,Based on 3 Risk Models • Family History BRCAPRO Claus Tyrer-Cusick • 35year-old woman Mother BC 33 19% 36% 28% Maternal aunt BC 42 • 35-year-old woman 23% 24% 32% Paternal aunt BC 29, OC 49 Paternal grandmother BC 35 • 35-year-old woman 18% 24% 31% Paternal aunt BC 29 Paternal grandmother BC 35 • 35-year-old woman 13% 18% 23% Mother BC 51 Maternal aunt BC 60

  25. Indications for Diagnostic MRI Lesion characterizations Mammographically dense breast Scar vs recurrent cancer Silicone augmented breast Neoadjuvant chemo – extent of disease Infiltrating lobular cancer – extent of disease Infiltrating ductal cancer – extent of disease Axillary adenopathy – primary unknown Post tissue reconstruction – recurrence Implant – integrity/ rupture ACR practice guideline

  26. SILICONE IMPLANT EVALUATION • MRI shown to be superior in detecting rupture Goodman C M et al, Ann Plas Surg. 1998:41:577-586 • Mean Sensitivity Mammography 28% Ultrasound 59% MRI 78%

  27. Silicone implants

  28. Silicone implants

  29. Indications for diagnostic MRI Invasion to deep fascia Contra lateral breast cancer Post lumpectomy residual disease – close margin on path Recurrence of cancer when other modalities inconclusive ACR practice guideline

  30. Evaluate for recurrent or contralateral tumor

  31. Evaluate for recurrent or contralateral tumor

  32. cysts

  33. cysts

  34. 32 yo with bx proven FA with new palpable lesion

  35. 32 yo with bx proven FA and new lesion

  36. 32 yo with bx proven FA

  37. 32 yo with bx proven FA

  38. 41 yo with palp nodule RUIQ

  39. 41 yo with palp nodule RUIQ

  40. 41 yo with palp nodule RUIQ

  41. 41 yo with palp nodule RUIQ

  42. 41 yo with palp nodule RUIQ

  43. MRI-GUIDED BREAST BIOPSY Appropriate for suspicious lesions found on MRI & not seen on mammography or US Equipment Needed: A dedicated breast coil A biopsy guidance system compatible with the breast coil and tissue sampling device A MR-compatible tissue sampling device: - 14 gauge cutting needle - 8-11 gauge vacuum-assisted sampling

More Related